Lionco(SH:603669)2025-04-25 09:35Financial Performance - The company's revenue for Q1 2025 was ¥50,121,123.94, a decrease of 34.79% compared to ¥76,861,627.55 in the same period last year[4] - The net loss attributable to shareholders was ¥18,621,240.46, compared to a loss of ¥16,041,506.14 in the previous year[4] - The basic and diluted earnings per share were both -¥0.03, compared to -¥0.02 in the same period last year[4] - The company reported a net loss of CNY 12,846,612.80 for Q1 2025, compared to a net loss of CNY 18,000,000 in Q1 2024[19] - The net profit for Q1 2025 was -18,621,240.46 RMB, compared to -16,041,506.14 RMB in Q1 2024, indicating a decline in profitability[20] - The total profit margin for Q1 2025 was -50.0%, compared to -22.3% in Q1 2024, indicating a worsening financial position[20] Assets and Liabilities - The total assets at the end of the reporting period were ¥1,231,431,435.30, a decrease of 1.90% from ¥1,255,333,587.55 at the end of the previous year[5] - Total assets decreased to CNY 1,231,431,435.30 as of March 31, 2025, from CNY 1,255,333,587.55 as of December 31, 2024[16] - Total liabilities decreased to CNY 480,286,617.26 as of March 31, 2025, from CNY 485,573,776.61 as of December 31, 2024[16] - The company’s inventory as of March 31, 2025, was CNY 23,300,966.11, down from CNY 27,879,613.88 as of December 31, 2024[15] - The company’s long-term equity investments decreased to CNY 14,584,608.81 as of March 31, 2025, from CNY 17,939,111.32 as of December 31, 2024[15] - The company’s total current assets were CNY 574,661,138.37 as of March 31, 2025, a decrease from CNY 586,610,563.80 as of December 31, 2024[15] Cash Flow - The net cash flow from operating activities was -¥13,569,961.60, an improvement from -¥20,674,871.45 in the previous year[4] - Operating cash flow for Q1 2025 was -13,569,961.60 RMB, an improvement from -20,674,871.45 RMB in Q1 2024[23] - The company had a net cash flow from financing activities of 2,008,404.39 RMB in Q1 2025, compared to -90,043,486.29 RMB in Q1 2024[24] - The company reported a total cash inflow from investment activities of 17,493,263.17 RMB in Q1 2025, compared to 87,327,929.61 RMB in Q1 2024[24] - Cash and cash equivalents as of March 31, 2025, were CNY 256,883,646.75, slightly up from CNY 254,087,208.94 as of December 31, 2024[14] - Total cash and cash equivalents at the end of Q1 2025 increased to 252,657,628.92 RMB from 282,930,347.78 RMB at the end of Q1 2024[24] Revenue and Operating Costs - The decline in revenue was primarily due to the impact of drug collection and price linkage policies, leading to continuous price declines and fluctuations in sales due to seasonal disease outbreaks[8] - Total operating costs for Q1 2025 were CNY 62,962,253.24, down 33.6% from CNY 94,759,740.05 in Q1 2024[19] - Operating income for Q1 2025 was CNY 50,121,123.94, while operating costs were CNY 36,073,102.81, resulting in a gross profit margin of approximately 28.1%[19] - Revenue from sales of goods and services in Q1 2025 was 37,359,969.68 RMB, down from 71,723,378.82 RMB in Q1 2024, reflecting a significant decrease[23] - The total operating expenses in Q1 2025 were 51,456,223.26 RMB, down from 102,528,017.32 RMB in Q1 2024[23] Shareholder Information - As of the end of the reporting period, the total number of common shareholders was 20,516, with the largest shareholder holding 47.09% of the shares[10] - The company repurchased 17,701,793 shares, representing 2.45% of the total shares outstanding[11] Government Support - The company received government subsidies amounting to ¥320,303.40 during the reporting period[6] Other Information - The weighted average return on net assets was -2.45%, down from -1.74% in the previous year[5] - The company did not report any net profit from subsidiaries prior to the merger in the current or previous period[21]